Leads Biolabs’ PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC

B NANJING, China, May 18, 2026 /PRNewswire/ — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its…
posteditor
posteditor
Articles: 21727

Other News